Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Oladapo Olumoroti Yeku, M.D., Ph.D.

Title
Institution
Department
Address
Phone

Research
The research activities and funding listed below are automatically derived from NIH ExPORTER and other sources, which might result in incorrect or missing items. Faculty can login to make corrections and additions.
  1. F31DK082280 (YEKU, OLADAPO O) Jul 1, 2008 - Sep 30, 2011
    NIH/NIDDK
    Facilitated insulin secretion via ablation of a compartmentalized pool of PIP2
    Role: Principal Investigator

Bibliographic
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
  1. Yeku O, Russo AL, Lee H, Spriggs D. A phase 2 study of combined chemo-immunotherapy with cisplatin-pembrolizumab and radiation for unresectable vulvar squamous cell carcinoma. J Transl Med. 2020 09 14; 18(1):350. PMID: 32928237.
    Citations:    
  2. Ramos A, Del Carmen M, Yeku O. PD-1 Inhibitor Therapy in a Patient with Preexisting P-ANCA Vasculitis: A Case Report and Review of the Literature. Case Rep Oncol Med. 2020; 2020:3428945. PMID: 32934857.
    Citations:    
  3. Zhao Y, Cao J, Melamed A, Worley M, Gockley A, Jones D, Nia HT, Zhang Y, Stylianopoulos T, Kumar AS, Mpekris F, Datta M, Sun Y, Wu L, Gao X, Yeku O, Del Carmen MG, Spriggs DR, Jain RK, Xu L. Losartan treatment enhances chemotherapy efficacy and reduces ascites in ovarian cancer models by normalizing the tumor stroma. Proc Natl Acad Sci U S A. 2019 02 05; 116(6):2210-2219. PMID: 30659155.
    Citations:    Fields:    
  4. Rafiq S, Yeku OO, Jackson HJ, Purdon TJ, van Leeuwen DG, Drakes DJ, Song M, Miele MM, Li Z, Wang P, Yan S, Xiang J, Ma X, Seshan VE, Hendrickson RC, Liu C, Brentjens RJ. Targeted delivery of a PD-1-blocking scFv by CAR-T cells enhances anti-tumor efficacy in vivo. Nat Biotechnol. 2018 10; 36(9):847-856. PMID: 30102295.
    Citations: 2     Fields:    
  5. Avanzi MP, Yeku O, Li X, Wijewarnasuriya DP, van Leeuwen DG, Cheung K, Park H, Purdon TJ, Daniyan AF, Spitzer MH, Brentjens RJ. Engineered Tumor-Targeted T Cells Mediate Enhanced Anti-Tumor Efficacy Both Directly and through Activation of the Endogenous Immune System. Cell Rep. 2018 05 15; 23(7):2130-2141. PMID: 29768210.
    Citations: 4     Fields:    
  6. Yeku OO, Purdon TJ, Koneru M, Spriggs D, Brentjens RJ. Armored CAR T cells enhance antitumor efficacy and overcome the tumor microenvironment. Sci Rep. 2017 09 05; 7(1):10541. PMID: 28874817.
    Citations: 10     Fields:    
  7. Yeku O, Li X, Brentjens RJ. Adoptive T-Cell Therapy for Solid Tumors. Am Soc Clin Oncol Educ Book. 2017; 37:193-204. PMID: 28561728.
    Citations: 3     Fields:    Translation:HumansCells
  8. Yeku O, Slovin SF. Radium-223 and concomitant therapies: prospects and prudence. Transl Androl Urol. 2016 Dec; 5(6):968-970. PMID: 28078234.
    Citations: 1     
  9. Yeku O, Slovin SF. Immune Therapy for Prostate Cancer. Cancer J. 2016 Sep/Oct; 22(5):334-341. PMID: 27749327.
    Citations: 2     Fields:    Translation:Humans
  10. Yeku OO, Brentjens RJ. Armored CAR T-cells: utilizing cytokines and pro-inflammatory ligands to enhance CAR T-cell anti-tumour efficacy. Biochem Soc Trans. 2016 Apr 15; 44(2):412-8. PMID: 27068948.
    Citations: 16     Fields:    Translation:HumansCells
  11. Yeku O, Slovin SF. Metabolism and pharmacokinetics of radium-223 in prostate cancer. Expert Opin Drug Metab Toxicol. 2015 May; 11(5):843-9. PMID: 25740232.
    Citations: 2     Fields:    Translation:HumansAnimals
  12. Tarhini AA, Lin Y, Yeku O, LaFramboise WA, Ashraf M, Sander C, Lee S, Kirkwood JM. A four-marker signature of TNF-RII, TGF-a, TIMP-1 and CRP is prognostic of worse survival in high-risk surgically resected melanoma. J Transl Med. 2014 Jan 23; 12:19. PMID: 24457057.
    Citations: 13     Fields:    Translation:Humans
  13. Ali H, Yeku O, Giesler D, Campbell-Massa R, Gao F, Amjad AI. Breast Mass and Lytic Bone Lesions: A Rare Presentation of Non-Hodgkin's Lymphoma Arising in the Breast. Case Rep Oncol Med. 2013; 2013:547171. PMID: 24228183.
    Citations:    
  14. Huang P, Yeku O, Zong H, Tsang P, Su W, Yu X, Teng S, Osisami M, Kanaho Y, Pessin JE, Frohman MA. Phosphatidylinositol-4-phosphate-5-kinase alpha deficiency alters dynamics of glucose-stimulated insulin release to improve glucohomeostasis and decrease obesity in mice. Diabetes. 2011 Feb; 60(2):454-63. PMID: 21270258.
    Citations: 5     Fields:    Translation:AnimalsCells
  15. Yeku O, Frohman MA. Rapid amplification of cDNA ends (RACE). Methods Mol Biol. 2011; 703:107-22. PMID: 21125486.
    Citations: 12     Fields:    
  16. Dall'Armi C, Hurtado-Lorenzo A, Tian H, Morel E, Nezu A, Chan RB, Yu WH, Robinson KS, Yeku O, Small SA, Duff K, Frohman MA, Wenk MR, Yamamoto A, Di Paolo G. The phospholipase D1 pathway modulates macroautophagy. Nat Commun. 2010; 1:142. PMID: 21266992.
    Citations: 63     Fields:    Translation:HumansAnimalsCells
  17. Yeku O, Scotto-Lavino E, Frohman MA. Identification of alternative transcripts using rapid amplification of cDNA ends (RACE). Methods Mol Biol. 2009; 590:279-94. PMID: 19763511.
    Citations:    Fields:    Translation:Cells
  18. Su W, Yeku O, Olepu S, Genna A, Park JS, Ren H, Du G, Gelb MH, Morris AJ, Frohman MA. 5-Fluoro-2-indolyl des-chlorohalopemide (FIPI), a phospholipase D pharmacological inhibitor that alters cell spreading and inhibits chemotaxis. Mol Pharmacol. 2009 Mar; 75(3):437-46. PMID: 19064628.
    Citations: 104     Fields:    Translation:HumansAnimalsCells
Local representatives can answer questions about the Profiles website or help with editing a profile or issues with profile data. For assistance with this profile: HMS/HSDM faculty should contact feedbackcatalyst.harvard.edu. For faculty or fellow appointment updates and changes, please ask your appointing department to contact HMS. For fellow personal and demographic information, contact HMS Human Resources at human_resourceshms.harvard.edu. For faculty personal and demographic information, contact HMS Office for Faculty Affairs at facappthms.harvard.edu.
Yeku's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts (104)
Explore
_
Co-Authors (6)
Explore
_
Similar People (60)
Explore
_
Same Department 
Explore
_
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.